Drugs & Aging

, Volume 28, Issue 4, pp 257–266 | Cite as

Erectile Dysfunction after Radical Prostatectomy

Treatment Options
Therapy In Practice

Abstract

Erectile dysfunction is a common problem after radical prostatectomy, with almost all men experiencing this complication for at least a short period after such surgery. There is evidence that early use of phosphodiesterase type 5 inhibitors, intracavernous vasoactive drugs, intraurethral alprostadil or vacuum devices can improve the recovery of postoperative erectile function. The same therapeutic modalities can be used to treat erectile dysfunction after radical prostatectomy. Physicians must be active and counsel patients and partners to improve adherence to penile rehabilitation or erectile dysfunction treatment.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The author has received speaker’s honoraria from Lilly, Pfizer and Bayer, and has received investigator grants from Lilly and Cristalia.

References

  1. 1.
    American Cancer Society. What are the key statistics about prostate cancer? [online]. Available from URL: http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancer-key-statistics [Accessed 2010 Jul 25]
  2. 2.
    INCA. Types of cancers: prostate [in Portuguese; online]. Available from URL: http://www2.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/prostata/ [Accessed 2010 Jul 25]
  3. 3.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. V.3.2010 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [Accessed 2010 Jul 26]
  4. 4.
    Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977–84PubMedCrossRefGoogle Scholar
  5. 5.
    Kundu SD, Roehl KA, Eggener SE, et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004; 172: 2227–31PubMedCrossRefGoogle Scholar
  6. 6.
    Sadovsky R, Basson R, Krychman M, et al. Cancer and sexual problems. J Sex Med 2010; 7: 349–73PubMedCrossRefGoogle Scholar
  7. 7.
    Bergman J, Gore JL, Penson DF, et al. Erectile aid use by men treated for localized prostate cancer. J Urol 2009; 182: 649–54PubMedCrossRefGoogle Scholar
  8. 8.
    Dubbelman Y, Wildhagen M, Schroder F, et al. Orgasmic dysfunction after open radical prostatectomy: clinical correlates and prognostic factors. J Sex Med 2010; 7: 1216–23PubMedCrossRefGoogle Scholar
  9. 9.
    Yu Ko WF, Degner LF, Hack TF, et al. Penile length shortening after radical prostatectomy: men’s responses. Eur J Oncol Nurs 2010; 14: 160–5PubMedCrossRefGoogle Scholar
  10. 10.
    Magheli A, Burnett AL. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol. 2009; 6: 415–27PubMedCrossRefGoogle Scholar
  11. 11.
    Mullerad M, Donohue JF, Li PS, et al. Functional sequelae of cavernous nerve injury in the rat: is there model dependency. J Sex Med 2006; 3: 77–83PubMedCrossRefGoogle Scholar
  12. 12.
    Walsh PC, Partin AW. Anatomical radical retropubic prostatectomy. In: Wein AJ, Kavoussi LR, Novick AC, et al., editors. Campbell-Walsh urology. 9th ed. Philadelphia (PA): Saunders Elsevier, 2007: 2956–78Google Scholar
  13. 13.
    Garcia FJ, Brock G. Current state of penile rehabilitation after radical prostatectomy. Curr Opin Urol. 2010; 20: 234–40PubMedCrossRefGoogle Scholar
  14. 14.
    Lue TF, Zeineh SJ, Schmidt RA, et al. Neuroanatomy of penile erection: its relevance to iatrogenic impotence. J Urol 1984; 131: 273–80PubMedGoogle Scholar
  15. 15.
    Hu J, Gu X, Stuart R, et al. Comparative effectiveness of minimally invasive vs. open radical prostatectomy. J Am Med Assoc 2009; 302: 1557–64CrossRefGoogle Scholar
  16. 16.
    Penson DF, Latini DM, Lubeck DP, et al. Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction to other causes? Results from the ExCEED data base. J Urol 2003; 169: 1458–61PubMedCrossRefGoogle Scholar
  17. 17.
    Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000; 283: 354–60PubMedCrossRefGoogle Scholar
  18. 18.
    McCammon KA, Kolm P, Main B, et al. Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. Urology 1999; 54: 509–16PubMedCrossRefGoogle Scholar
  19. 19.
    Nelson CJ, Deveci S, Stasi J, et al. Sexual bother following radical prostatectomy. J Sex Med 2010; 7: 129–35PubMedCrossRefGoogle Scholar
  20. 20.
    Kornblith AB, Herr HW, Ofman US, et al. Quality of life of patients with prostate cancer and their spouses: the value of a data base in clinical care. Cancer 1994; 73: 2791–802PubMedCrossRefGoogle Scholar
  21. 21.
    Kava BR. Advances in the management of post-radical prostatectomy erectile dysfunction: treatment strategies when PDE-5 inhibitors don’t work. Rev Urol 2005; 7: S39PubMedGoogle Scholar
  22. 22.
    Wespes E, Amar E, Hatzichristou D, et al. EAU guidelines on erectile dysfunction: an update. Eur Urol 2006; 49: 806–15PubMedCrossRefGoogle Scholar
  23. 23.
    Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: the management of erectile dysfunction: an AUA update. J Urol 2005; 174: 230–9PubMedCrossRefGoogle Scholar
  24. 24.
    Zippe CD, Jhaveri FM, Klein EA, et al. Role of Viagra after radical prostatectomy. Urology 2000; 55: 241–5PubMedCrossRefGoogle Scholar
  25. 25.
    Hatzimouratidis K, Burnett AL, Hatzichristou D, et al. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol 2009; 55: 334–47PubMedCrossRefGoogle Scholar
  26. 26.
    Montorsi F, McCullough A. Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. J Sex Med. 2005; 2: 658–67PubMedCrossRefGoogle Scholar
  27. 27.
    Ohebshalom M, Parker M, Waters B, et al. Erectile haemodynamic status after radical prostatectomy correlates with erectile functional outcome. BJU Int 2008; 102: 592–6PubMedCrossRefGoogle Scholar
  28. 28.
    Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170: 1278–83PubMedCrossRefGoogle Scholar
  29. 29.
    Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26: 777–83PubMedCrossRefGoogle Scholar
  30. 30.
    Montorsi F, Nathan HP, McCullough A, et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 2004; 172: 1036–41PubMedCrossRefGoogle Scholar
  31. 31.
    Paick JS, Kim SW, Yang DY, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med 2008; 5: 946–53PubMedCrossRefGoogle Scholar
  32. 32.
    Glina S, Fonseca GN, Bertero EB, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med 2010; 7: 1928–36PubMedCrossRefGoogle Scholar
  33. 33.
    Paick JS, Ahn TY, Choi HK, et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008 Nov; 5(11): 2672–80PubMedCrossRefGoogle Scholar
  34. 34.
    Heaton JP, Morales A, Adams MA, et al. Recovery of erectile function by the oral administration of apomorphine. Urology 1995; 45: 200–6PubMedCrossRefGoogle Scholar
  35. 35.
    Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety ofonce-a-day dosingoftadalafil 5 mgand 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50: 351–9PubMedCrossRefGoogle Scholar
  36. 36.
    Masterson TA, Serio AM, Mulhall JP, et al. Modified technique for neurovascular bundle preservation during radical prostatectomy: association between technique and recovery of erectile function. BJU Int 2008; 101: 1217–22PubMedCrossRefGoogle Scholar
  37. 37.
    Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol. 2008; 18: 613–20PubMedCrossRefGoogle Scholar
  38. 38.
    Mulhall JP, Morgentaler A. Penile rehabilitation should become the norm for radical prostatectomy patients. J Sex Med. 2007; 4: 538–43PubMedCrossRefGoogle Scholar
  39. 39.
    Montorsi F, Guazzoni G, Strambi LF, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 1997; 158: 1408–10PubMedCrossRefGoogle Scholar
  40. 40.
    Mulhall J, Land S, Parker M, et al. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2005; 2: 532–40PubMedCrossRefGoogle Scholar
  41. 41.
    Mulhall JP, Bella AJ, Briganti A, et al. Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med 2010; 7: 1687–98PubMedCrossRefGoogle Scholar
  42. 42.
    Lee CH, Shin JH, Ahn GJ, et al. Udenafil enhances the recovery of erectile function and ameliorates the pathophysiological consequences of cavernous nerve resection. J Sex Med 2010; 7: 2564–71PubMedGoogle Scholar
  43. 43.
    Padma-Nathan H, McCullough AR, Levine LA, et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20: 479–86PubMedCrossRefGoogle Scholar
  44. 44.
    Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol. 2004; 171: 771–4PubMedCrossRefGoogle Scholar
  45. 45.
    Bannowsky A, Schulze H, van der Horst C, et al. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int 2008; 101: 1279–83PubMedCrossRefGoogle Scholar
  46. 46.
    Montorsi F, Brock G, Lee J, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008; 54: 924–31PubMedCrossRefGoogle Scholar
  47. 47.
    Mulhall JP. Does on-demand vardenafil improve erectile function recovery after radical prostatectomy? Nat Clin Pract Urol. 2009; 6: 14–5PubMedCrossRefGoogle Scholar
  48. 48.
    Deho F, Gallina A, Salonia A, et al. Prophylaxis of erectile function after radical prostatectomy with phosphodiesterase type 5 inhibitors. Curr Pharm Des 2009; 15: 3496–501PubMedCrossRefGoogle Scholar
  49. 49.
    Mulhall JP, Parker M, Waters BW, et al. The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. BJU Int 2010; 105: 37–41PubMedCrossRefGoogle Scholar
  50. 50.
    User HM, Hairston JH, Zelner DJ, et al. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol 2003; 169: 1175–9PubMedCrossRefGoogle Scholar
  51. 51.
    Bosshardt RJ, Farwerk R, Sikora R, et al. Objective measurement of the effectiveness, therapeutic success and dynamic mechanisms of the vacuum device. BJU 1995; 75: 786–91PubMedCrossRefGoogle Scholar
  52. 52.
    Raina R, Agarwal A, Ausmundson S, et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res 2006; 18: 77–81PubMedCrossRefGoogle Scholar
  53. 53.
    Dalkin BL, Christopher BA. Preservation of penile length after radical prostatectomy: early intervention with a vacuum erection device. Int J Impot Res. 2007; 19: 501–4PubMedCrossRefGoogle Scholar
  54. 54.
    Kohler TS, Pedro R, Hendlin K, et al. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int 2007; 100: 858–62PubMedCrossRefGoogle Scholar
  55. 55.
    Raina R, Pahlajani G, Agarwal A, et al. Long-term potency after early use of a vacuum erection device following radical prostatectomy. BJU Int 2010; 106(11): 1719–22PubMedCrossRefGoogle Scholar
  56. 56.
    Costabile RA, Spevak M, Fishman IJ, et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1998; 160: 1325–8PubMedCrossRefGoogle Scholar
  57. 57.
    Raina R, Agarwal A, Zaramo CE, et al. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res 2005; 17: 86–90PubMedCrossRefGoogle Scholar
  58. 58.
    McCullough AR, Hellstrom WG, Wang R, et al. Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. J Urol 2010; 183: 2451–6PubMedCrossRefGoogle Scholar
  59. 59.
    Teloken P, Mesquita G, Montorsi F, et al. Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners. J Sex Med 2009; 6: 2032–8PubMedCrossRefGoogle Scholar
  60. 60.
    Virag R. Intracavernous injection of papaverine for erectile failure [letter]. Lancet 1982; 2: 938PubMedCrossRefGoogle Scholar
  61. 61.
    Sidi AA, Reddy PK, Chen KK. Patient acceptance of and satisfaction with vasoactive intracavernous pharmacotherapy for impotence. J Urol. 1988; 140: 293–4PubMedGoogle Scholar
  62. 62.
    Gheorghiu S, Godschalk M, Gentili A, et al. Quality of life in patients using self-administered intracavernous injections of prostaglandin E1 for erectile dysfunction. J Urol 1996; 156: 80–1PubMedCrossRefGoogle Scholar
  63. 63.
    Alexandre B, Lemaire A, Desvaux P, et al. Intracavernous injections of prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life on long-term treatment. J Sex Med 2007; 4: 426–31PubMedCrossRefGoogle Scholar
  64. 64.
    Dennis RL, McDougal WS. Pharmacological treatment of erectile dysfunction after radical prostatectomy. J Urol. 1988; 139: 775–6PubMedGoogle Scholar
  65. 65.
    Baniel J, Israilov S, Segenreich E, et al. Comparative evaluation of treatments for erectile dysfunction in patients with prostate cancer after radical retropubic prostatectomy. BJU Int 2001; 88: 58–62PubMedCrossRefGoogle Scholar
  66. 66.
    Raina R, Lakin MM, Thukral M, et al. Long-term efficacy and compliance of intracorporal (IC) injection for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res 2003; 15: 318–22PubMedCrossRefGoogle Scholar
  67. 67.
    Claro JA, Aboim JE, Maríngolo M, et al. Intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: an observational study. Sao Paulo Med J 2001 5; 119: 135–7Google Scholar
  68. 68.
    Albaugh J, Ferrans CE. Patient-reported pain with initial intracavernosal injection. J Sex Med. 2009; 6: 513–9PubMedCrossRefGoogle Scholar
  69. 69.
    Vrijhof HJ, Delaere KP. Vacuum constriction devices in erectile dysfunction: acceptance and effectiveness in patients with impotence oforganic or mixed aetiology. Br J Urol. 1994; 74: 102–5PubMedCrossRefGoogle Scholar
  70. 70.
    Turner LA, Althof SE, Levine SB, et al. Treating erectile dysfunction with external vacuum devices: impact upon sexual, psychological, and marital functioning. J Urol 1990; 144: 79–82PubMedGoogle Scholar
  71. 71.
    McCullough AR. Prevention and management of erectile dysfunction following radical prostatectomy. Urol Clin North Am. 2001; 28: 613–27PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Instituto H. EllisSão Paulo-SPBrazil

Personalised recommendations